Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $121 ...

Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Recent acquisitions are masking Vertex's slower organic growth, which doesn't justify its current stock price. Without acquisitions, Vertex's new customer expansion in 2024 has been very limited.

The highest price of Vertex Securities Ltd stock is ₹7.36 in the last 52-week ... key details MSCI India rejig: Adani Green Energy out, Hyundai Motor in; Jai Corp sees smallcap index exclusion ...

Vertex stock trades at 23.8 times forward earnings (in line with the S&P 500), with $11.2 billion in cash and strong growth prospects. The healthcare sector has struggled to deliver worthwhile ...